ERBB2 and breast carcinoma: Preclinically, trastuzumab has been observed to increase CD11c and F4/80 (markers of dendritic cells and macrophages, respectively) in in vivo models of HER2 + breast cancer, highlighting the immunogenic potential of anti-HER2 therapy [15].